ImmunityBio: A Small Bet Is Warranted (NASDAQ:IBRX)

Group 1 - ImmunityBio, Inc. (NASDAQ: IBRX) shares have decreased nearly 66% over the past 18 months due to cash needs leading to a 37% dilution [1] - The company is focused on immunotherapy and vaccine development, with its key product being the IL-15 super-agonist fusion protein Anktiva [1]